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Introduction
Pediatric malignancies are relatively rare and account for 0.5%
of all cancers. The annual incidence varies between 110 and 150
per million children, which means that the chance for a child to
develop a cancer during the first 15 years of life is 1:450–600.
Leukemias and tumors of the brain and spinal cord have the high-
est relative incidence rates, followed in frequency by neuroblasto-
ma, lymphomas, Wilms tumor and bone tumors. Other tumor types
are less frequent. Pediatric tumors arise as a result of disturbance
of genetic material. In very young children predominantly blaste-
mal tumors (e.g. nephroblastoma, neuroblastoma, medulloblas-
toma) occur, whereas in the age group 10–25 years sarcoma’s
(e.g. osteosarcoma, EWING sarcoma) are dominating. Carcino-
mas are typically adult-type tumors (> 30 years of age).
The overall survival rate for childhood cancers has improved
significantly over the years (from 25% in the 1960’s to 75% in the
1990’s). This means that the pool of children and adults, who have
survived childhood cancer and who are in follow up and being
studied for potential late effects, is continuously increasing [1].
In recent years the contribution of nuclear medicine has been
of increasing interest to pediatric oncology, in particular in imag-
ing for diagnosis, staging and follow-up, in quantitative function
analysis of organs at risk during oncological therapy, as well as in
radionuclide therapy [2–5]. Nuclear medicine studies in children
require special considerations regarding the performance of the
procedure and the attitude of the attending staff [6].
In tumor imaging the trend has been to use more or less spe-
cific tumor-seeking radiopharmaceuticals. A great number of these
agents are available, exploiting various metabolic and biological
properties of individual tumors. Parallel to these developments
radionuclide therapy becomes more widely used, whenever its
success is envisaged on the basis of a good and selective uptake
and long retention of the radiopharmaceutical in the tumor. Table 1
shows a list of tumor seeking radiopharmaceuticals, which are
currently available for diagnosis and therapy of pediatric tumors.
The major indications, in which nuclear medicine has a role, are
discussed below.
Table 1. Tumor-seeking radiopharmaceuticals and indications in
pediatric oncology
Purpose Radiopharmaceutical Indications
Imaging  67Ga-citrate Lymphoma
201Tl-chloride Differentiated thyroid ca.
Lymphoma
Osteosarcoma
Brain tumors
Rhabdomyosarcoma
99mTc-sestamibi Lymphoma
99mTc-tetrofosmin Lymphoma
99mTc-diphosphonate Osteosarcoma
99mTc-pentavalent DMSA Medullary thyroid ca.
(M.E.N. II syndromes
123I/131I-MIBG Neuroblastoma
Pheochromocytoma
Ganglioneuroma
111In-pentetreotide Neuroendocrine tumors
Lymphoma
99mTc-HIDA derivatives Hepatoblastoma
111In-antimyosin Fab Rhabdomyosarcoma
radiolabeled antibodies Neuroblastoma
(3F8, ch14.18, chCE7)
PET 18F-deoxyglucose Lymphoma
Neuroblastoma
124I-MIBG Neuroblastoma
124I-3F8 antibodies Neuroblastoma
11C-hydroxyephedrine Neuroblastoma,
Pheochromocytoma
Therapy 131I-iodide Differentiated thyroid ca.
131I-MIBG Neuroblastoma
125I-MIBG Neuroblastoma
131I-3F8 antibodies Neuroblastoma
131I-Rose Bengal Hepatoblastoma
131I-antiferritin antibodies Hepatoblastoma
89Sr-chloride Osteosarcoma
186Re-HEDP Osteosarcoma
153Sm-EDTMP Osteosarcoma
131I-anti CD20 antibodies Lymphoma
90Y-anti CD20 antibodies Lymphoma
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Tumor imaging
Bone tumors
The principle bone tumors in children are osteosarcoma (inci-
dence rate 1.6–2.6/106 children per year) and EWING sarcoma
(incidence 0.6/106/year). The peak incidence is between 10 and
20 years of age and etiological factors include rapid growth, trau-
ma, radiation and previous chemotherapy. Patients generally
present with bone pain, swelling of bone with or without functional
impairment. The distribution of the sites of the primary tumor is
different for both tumor types.
Relevant diagnostic procedures are X-ray, CT, MRI, bone scin-
tigraphy and SPECT, alkaline phosphatase (osteosarcoma) and LDH
(EWING sarcoma). The diagnosis is confirmed by histology and im-
munocytochemistry. Osteosarcoma is treated by surgery (i.e. resec-
tion/amputation/rotationplasty) after preoperative chemotherapy, fol-
lowed by postoperative chemotherapy, prosthetics and rehabilita-
tion therapy. EWING sarcoma is treated by radiotherapy or surgical
resection of an expendable bone and chemotherapy [1].
Bone scintigraphy is highly sensitive to detect EWING sarco-
ma and bone metastases.
In differentiated osteosarcoma, bone scintigraphy/SPECT us-
ing 99mTc-diphosphonate may, as a result of its targeting the tu-
mor-produced osteoid, visualize not only the primary bone tumor
and its skeletal metastases with great intensity and 100% sensi-
tivity, but also the extraosseous metastases in the majority of cas-
es, regardless their localization [7, 8]. SPECT can be helpful to
distinguish extraosseous from skeletal metastases, particularly in
the thorax and pelvis [9]. To study the effect of preoperative che-
motherapy in osteosarcoma also Thallium-201 scintigraphy has
been used with success [10].
Lymphoma
The 3rd most common childhood malignancy (16.4/106 chil-
dren) occurs as Hodgkin’s disease or (more often) as non-Hodgkin
lymphoma of the B-cell- or T-cell type. The diagnosis is based on
histopathology and immunocytology of lymph nodes, bone ma-
rrow, cerebrospinal fluid or effusions [1]. Structural (anatomical)
diagnostic imaging is done by X-ray, ultrasonography of the ab-
domen, CT-scan of chest/abdomen (poor for bone marrow) and
MRI (good for bone marrow). Nuclear medicine provides func-
tional imaging, i.e. bone scintigraphy and tumor imaging (planar
scintigraphy/SPECT/PET) using 67Ga-citrate, 201Tl-chloride, 99mTc-
-sestamibi, 111In-pentetreotide and 18F-FDG.
67Ga-citrate has been used for decades in the detection and
staging of lymphoma [11]. 67Ga-SPECT is better than planar scin-
tigraphy (sensitivity 97% vs. 67% for lymphoma in the chest) [12].
More recently it is also used for early recognition of response to
chemotherapy or radiotherapy: failure of a positive 67Ga-scan to
convert to negative is associated with a poor prognosis. In follow
up 67Ga-scintigraphy is better than CT-scan in differentiating re-
sidual tumor from fibrosis.
201Tl-chloride scintigraphy and emission tomography and positron
emission tomography (PET) using 18F-deoxyglucose can also be used
for this purpose. Especially in low grade non-Hodgkin lymphoma
201Tl-chloride scintigraphy is superior to 67Ga-imaging [13].
More recently 99mTc-sestamibi and 99mTc-tetrofosmin have been
used for imaging lymphoma; these tracers add the aspect of tu-
mor characterization, because of their association with p-glyco-
protein, which plays a role in multi-drug resistance [14].
Thyroid carcinoma
Thyroid carcinoma is rare in childhood (0.5–1.5% of pediatric
malignancies); 72% are of the papillary type, 18% follicular and
around 10% medullary carcinoma. The diagnostic and therapeu-
tic approach in children is not essentially different from that in
adults: diagnosis by ultrasonography, thyroid scintigraphy and
fine needle aspiration, treatment by surgery and postoperative
131I-therapy. Subsequently, diligent surveillance of the tumor mark-
er thyroglobulin (should not be detectable after adequate surgery
and 131I-ablation) and 123I- or 131I-scintigraphy either at regular inter-
vals or whenever a rise in serum Tg is detected, is mandatory [1].
201Tl-chloride scintigraphy, in conjunction with thyroglobulin
assays in serum, has become a reliable alternative to the use of
131I-iodide in the follow-up of differentiated thyroid carcinoma, par-
ticularly as the procedure and radiation dose to the child com-
pares favorably with that of 131I [15]. 131I maintains its role in radio-
nuclide therapy of thyroid carcinoma. In case of iodine-non-avid-
ity of metastases, alternative tumor-seeking radiopharmaceuticals
may be used, e.g. 201Tl-chloride, 99mTc-sestamibi, 111In-pentet-
reotide, 67Ga-citrate and 18F-FDG.
Medullary thyroid carcinoma arises from the parafollicular or
C-cells and may present as sporadic cases or as a familial dis-
ease in association with other endocrine tumors (25%). In the lat-
ter form, children may become involved in the family screening of
MEN 2 syndromes. A variety of tracers can be used to demonstrate
medullary thyroid carcinoma: 201Tl-chloride, 99mTc-pentavalent
DMSA, 99mTc-sestamibi, 123I- or 131I-MIBG, 111In-pentetreotide,
131I-labeled anti-CEA antibodies and 18F-FDG. Both 201Tl- and
99mTc(V)-DMSA scintigraphy have a high sensitivity (> 80%), but
are aspecific tracers, whereas MIBG and antibodies are highly spe-
cific, but have a low sensitivity (35% and 60% respectively) [16].
Neuroblastoma
Neuroblastoma is a malignant tumor of the sympathetic ner-
vous system, occurring most frequently in early childhood: 50%
of patients are younger than 2 years, 75% are younger than 4 and
the disease is rare after the age of 14. The incidence in US chil-
dren is 5/106 population per year, with a slight preponderance of
males and white-skinned people. The site of the primary tumor
varies: 70% of all tumors originate in the retroperitoneal region,
including around 30% in the adrenal gland and 10% in the ab-
dominal sympathetic side chain, and 8% occur in the cervical,
17% in the thoracic and 5% in the pelvic sympathetic side chain.
The diagnosis is suspected on clinical symptomatology, which
varies with the site and size of the tumor and the amount cate-
cholamines, which more than 90% of these tumors produce in
excess, and is confirmed by increased levels of catecholamines
and metabolites in urine and by MIBG scintigraphy [1].
Specific targeting of neuroblastoma may be achieved either
via the metabolic route (MIBG), via receptor binding (peptides) or
via the immunological route (antibodies).
An active uptake-1 mechanism at the cell membrane and neu-
rosecretory storage granules in the cytoplasm of neural crest tu-
mours are responsible for the specific uptake and retention of
131I-MIBG respectively. As nonadrenergic tissues rely on passive
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diffusion only, this results in high tumor/non-tumor ratio’s.
A number of drugs may interfere with the uptake and/or retention
of 131I-MIBG (Table 2) [17].
Bone scintigraphy may reveal increased uptake at the site of
the primary tumor and is a sensitive, but aspecific technique to
demonstrate bone metastases, especially when these are locat-
ed in/near the epiphyses.
As 123I- or 131I-MIBG scintigraphy has a cumulative sensitivity
of 92% and is a highly specific procedure in children, this has
become the procedure of choice for detection, staging and follow
up of neuroblastoma. It can detect the primary tumor, residual or
recurrent disease and nodal or distant metastases, regardless
their localization, in a single procedure [18, 19]. Due to the high
specificity, it can also establish the diagnosis of neuroblastoma,
ruling out other pediatric tumors [20]. Moreover, 123I-MIBG scin-
tigraphy can assist in probe-guided surgery of tumor residu or
recurrence, and MIBG tracer studies can identify patients who are
likely to benefit from therapy using 131I-MIBG. For diagnostic scin-
tigraphy both 123I-MIBG and 131I-MIBG are available: a comparison
of these tracers showed that results are not essentially different,
but, as the image quality of 123I-MIBG images is generally better,
this agent is preferred for diagnosis and follow up scans [21].
131I-MIBG allows delayed imaging which may be preferred for
assessing both the tumor uptake and retention prior to therapy.
Potential pitfalls in MIBG scintigraphy in neuroblastoma are
abnormalities which are located in or close to normal structures
that normally take up MIBG (123I-MIBG SPECT may be helpful in
these cases [22]), hyperplasia of the residual adrenal gland after
contralateral adrenalectomy, hydronephrosis, contamination, ac-
tivity in the reservoir of an administration system or in intravenous
lines or in drains, inadequate blockade of the thyroid, and uptake
in benign or malignant tumors other than neuroblastoma which
can concentrate MIBG.
On the basis of peptide receptor binding (somatostatine re-
ceptors have been found in 86% of neuroblastomas and VIP re-
ceptors in 57% [23]), the cumulative sensitivity of 111In-pentetreotide
is 77% [19].
In the eighties murine monoclonal antibodies 131I-UJ13A and
131I-3F8 were used for diagnosis and treatment of neuroblastoma.
More recently, chimeric antibodies, e.g. ch14.18 and chCE7 have
been developed yielding high specific tumor uptakes in neuro-
blastoma-bearing nude mice and initial results of scintigraphy in
patients are promising [24].
As most neuroblastomas are highly differentiated tumors,
positron emission tomography (PET) using 18F-deoxyglucose
(FDG) has a lower sensitivity than MIBG-scintigraphy [25], how-
ever the more specific 11C-hydroxyephedrin (HED) has been used
with success to image neuroblastoma [26] and 124I-labeled MIBG
and 3F8 antibodies for dosimetry prior to therapy.
Rhabdomyosarcoma
Eight percent of pediatric malignancies are rhabdomyosarco-
mas, which occur in two peaks, one between 1 and 7 years of
age, the other between 15 and 20 years. The primary location is
most frequently in the head&neck area (36%) and the genitouri-
nary tract (25%). The diagnosis is confirmed by a biopsy with im-
munohistochemical staining of the myosin, which is characteristic
for this tumor and forms the basis for radioimmunoscintigraphy.
Treatment consists of preoperative chemotherapy or radiothera-
py, followed by surgery of the primary tumor and regional lymph
nodes and postoperative chemotherapy [1].
Aspecific tracers, e.g. 67Ga-citrate, 201Tl-chloride and 18F-deoxy-
glucose (PET), can be used to image rhabdomyosarcoma [27, 28].
Specific targeting of rhabdomyosarcoma is provided by  radioim-
munoscintigraphy using 111In antimyosin Fab fragments [29], how-
ever this radiopharmaceutical is no longer commercially available.
Hepatoblastoma
Liver tumors are rare in children and the incidence and distri-
bution of tumor types vary with geography. The most frequent
type is hepatoblastoma, which usually presents with abdominal
distension, palpable mass or hepatomegaly. Serum assays of
a-foetoprotein, produced by the tumor, serve as a tumormarker.
Treatment is by surgery (hepatic lobectomy, which is better toler-
ated by children than adults) and chemotherapy (either systemic
or intra-arterial); inoperable or recurrent tumors may also be treat-
ed by hepatic arterial embolization and intra-arterial radionuclide
therapy [1].
67Ga-citrate scintigraphy and SPECT may be used for (aspe-
cific) tumor imaging. Some hepatoblastomas have retained their
capability to take up hepatobiliary agents, such as 99mTc-HIDA
derivatives, and tumor retention of these agents may be demon-
strated by hepatobiliary scintigraphy [30].
Miscellaneous
Apart from tumor imaging, scintigraphy of organs, e.g. of bone,
bone marrow, thyroid lungs, kidneys, brain, liver/spleen and lymph-
nodes, is also widely used in pediatric oncology. Scintigraphy using
99mTc-labeled autologous erythrocytes may be helpful to differen-
tiate hemangioma from other tumors.
New tracers
The recent trend in oncology to tailor therapy to the individual
patient has led to the development of specific tracers which allow
characterization of the tumor rather then detection. Using such
tracers, a negative result, which in terms of tumor detection would
be considered a “false negative”, may be just as meaningful as
Table 2. Medication interfering with MIBG-uptake and/or retention
(mechanism: a — uptake-1 inhibition, b — depletion, c — transport
inhibition, d — uncertain)
Drugs known to interfere Drugs expected to interfere
Labetalol [a, b] Adrenergic blocking agents [b]:
e.g. bretylium, guanethidine
Reserpine [b, c] Sympathicomimetics [b]:
e.g. amphetamine, dopamine,
isoproterenol, terbutaline
Calcium-channel blockers [d]: Phenothiazides [a]:
e.g. nifedipine, verapamil e.g. chlorpromazine, promethazine
Tricyclic antidepressants [a]: Butyrophenones [a]:
e.g. amitryptiline, imipramine e.g. droperidol, haloperidol,
Sympathicomimetics [b]: Thioxanthines [a]
e.g. ephedrine
Cocaine [a] Maprotiline, trazolone [a]
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a positive result. Although most of these agents are undergoing
clinical investigation in adult patients, they will in time be used in
pediatric oncology too.
99mTc-sestamibi, a cationic complex which is taken up in mito-
chondria, may be removed from the cell by P-glycoprotein which
is associated with multiple drug resistance; in children with lym-
phoma, inability of the tumor to retain 99mTc-sestamibi was found
to be correlated with a poor response to chemotherapy [14].
Other examples (in adults) of scintigraphic tumor character-
ization are the use of 123I-estradiol which binds to estrogen recep-
tors, 123I-IAZA, 18F-misonidazole and 99mTc-labeled metal-complexes
highlighting tumor hypoxia, and 99mTc-annexin V indicating apop-
tosis.
New techniques
Positron emission tomography using 18F-deoxyglucose is grad-
ually gaining recognition in pediatric oncology, although in chil-
dren special considerations and preparations are required to en-
sure a flawless i.v. injection of the tracer, sufficient patient rest
prior to and after the tracer administration and immobilization dur-
ing the entire acquisition time. Pediatric indications for 18F-FDG
PET include brain tumors, osteosarcoma, EWING sarcoma, rhab-
domyosarcoma, WILMS tumor and lymphoma [31]. Neuroblasto-
ma can better be detected with a highly specific single photon
tracer such as 123I-MIBG than with the aspecific 18F-FDG [25].
However, as specific agent, 11C-hydroxyephedrine can be used
for PET of pheochromocytoma and neuroblastoma [26].
Positron emission tomography is particularly useful for the stag-
ing prior to surgery or radiotherapy, for the planning of radiother-
apy by 3-dimensional matching of functional and anatomical pa-
rameters, and for monitoring response to therapy. One must be
aware that, in children, 18F-FDG uptake in normal thymus tissue
may cause false-positive results in the mediastinum.
Other new technology is the intraoperative use of gamma-
probes and minicamera in pediatric surgery to facilitate tumor re-
section. E.g. after previous surgery of neuroblastoma, resection
of tumor residu or recurrence may be difficult: radioguided sur-
gery after administration of 123I-MIBG may allow the detection of
the lesion and determination of the completeness of resection
[32]. The same principle applies to the use of other tumor seeking
agents for other malignancies.
Function monitoring
As a functional modality nuclear medicine is well suited to
monitor the function of organs at risk during treatment in pediatric
oncology, in particular cardiac, pulmonary, renal and salivary func-
tion. Anthracycline- or radiation induced cardiomyopathy is stud-
ied monitoring the ejection fraction by gated analysis and myo-
cardial damage has been assessed using 111In-antimyosin anti-
bodies. Pulmonary ventilation and perfusion studies and 111In-pen-
tetreotide scintigraphy are used to detect radiation lesions to the
lungs and monitor the success of their treatment with corticoster-
oids. Renography with 99mTc-DTPA or 99mTc-MAG3 and renal up-
take studies using 99mTc-DMSA can monitor radiation nephropa-
thy and renal consequences of Ifosfamide and Cisplatin treatment
[33]. Radiation lesions to the salivary glands after 131I-therapy or
external beam radiotherapy to the neck can be monitored by mea-
suring salivary gland 99mTc-pertechnetate secretion and excretion.
Radionuclide therapy
Considerations
As an oncological treatment modality, radionuclide therapy
combines the advantages of being systemic, like chemotherapy,
with that of delivering local radiation to tumors, like radiotherapy.
Apart from attaining objective response, radionuclide therapy can
provide excellent palliation, as it is associated with limited side
effects and few late effects.
However, handicaps for this modality are the need of isolation
of patients and storage of radioactive waste, the insufficient avail-
ability of suitable isolation facilities and the high cost of the newer
therapeutic agents [34].
Multiple mechanisms for targeting radionuclides to tumors pre-
vail; in children, current indications are differentiated thyroid carci-
noma, neuroblastoma, osteosarcoma, painful skeletal metastases
and, in future, lymphoma. Contraindications are severe myelosup-
pression and renal function disorders, as well as an instable patient
condition not allowing isolation therapy or lack of understanding of
or cooperation with guidelines for radiation protection.
Special considerations apply for the treatment of children with
radionuclides [35].
Problems of isolating a child may be minimized by inviting
parents or other relatives to become actively involved in the care
of the child. They can stay in an adjacent room with closed circuit
television and intercom and must be instructed about issues of
radiation protection: to wear disposable gown, gloves and shoes
and carry a pocket dose-meter, when entering the isolation room;
to restrict the time of exposure, keep as much distance as feasible,
not to drink or eat in this room and how to handle any radioactive
waste; in case of 131I-containing treatment, the carer uses potassi-
um iodide (200 mg daily orally) for thyroid blockade. If these condi-
tions are met, participation of relatives is both feasible and safe,
with measured and estimated radiation doses varying 0.4–3 mSv.
The child must be kept busy and amused, e.g. by drawing/
/reading material, toys, (computer) games, video-films, etc. Child
and parents should be made aware, that items which become
contaminated may have to be stored for radioactive decay.
In general, both the radionuclide therapy and the isolation are
well tolerated by children. Potential hazards are acute radiation
effects, like nausea, vomiting, sialoadenitis or temporary swelling
of tumor localizations; or side effects due to the targeting agent,
e.g. allergic reactions and HAMA response to antibodies, vaso-
active reaction to MIBG. Potential long-term effects are hemato-
logical effects, xerostomy, induction of leukemia or other malig-
nancies; it should be emphasized, however, that long-term follow
up studies have demonstrated that radionuclide therapy carries
a much lower risk of leukemia and second cancers than chemo-
therapy and external beam radiotherapy.
Thyroid carcinoma
As in adults, radioiodine therapy is indicated in children with
differentiated thyroid carcinoma, either for ablation of thyroid rem-
nants after (near)total thyroidectomy or for treatment of tumor re-
currence or metastases.
131I-therapy of metastatic thyroid carcinoma has proven effica-
cy, both in terms of objective response and survival rates. Follow-
ing the Chernobyl accident in 1986, the incidence rates of pediatric
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thyroid cancer have risen significantly in countries affected by fall
out. Many of these children presented with stage T4 tumors, multi-
focal tumors, and metastases in lymph nodes and lungs. In a group
of patients from Belarus, treated with 131I in Germany under a coop-
erative project of the European Commission, the overall percent-
age of complete remission was 64%, i.e. 95% for lymph node me-
tastases, but only 40% for pulmonary metastases [36].
In long-term follow up of surviving young thyroid carcinoma
patients, induction of second malignancies and fertility disorders
are rarely seen. Girls treated with 131I at young age generally have
normal pregnancies and healthy offspring later on.
In children with recurrent or metastatic medullary therapy car-
cinoma radionuclide therapy (by targeting with MIBG, peptides or
antibodies) may also be considered.
Neuroblastoma
Since 1984 therapeutic doses of 131I-MIBG have been adminis-
tered to children with metastatic or recurrent neuroblastoma failing
conventional treatment [35]. Pooled results of major centers indi-
cate an objective response rate of 51% (Tab. 3). Most patients
had stage IV, progressive and intensely pretreated disease and
were only treated with 131I-MIBG when other treatment modalities
had failed. Both the 131I-MIBG therapy and the isolation are general-
ly well tolerated by children; hematological side effects may occur.
For patients with recurrent and progressive disease after conven-
tional treatment 131I-MIBG therapy is probably the best palliative treat-
ment, as its invasiveness and toxicity compare favorably with that
of chemotherapy and external beam radiotherapy [37, 38].
The therapeutic effect of 131I-MIBG may be increased by com-
bining it with chemotherapy and/or total body irradiation, but this
is associated with severe toxicity. Less toxic is the combination of
131I-MIBG therapy with oxygen treatment under hyperbaric condi-
tions, by which the tumor cell is exposed to the toxic effect of
hydroxyl radicals in addition to the radiation effect [39].
More recently, 131I-MIBG therapy has been integrated in the
treatment protocol as the initial therapy instead of preoperative
combination chemotherapy in children presenting with advanced
disease/inoperable neuroblastoma. The objective is to reduce the
tumor volume, enabling adequate surgical resection and to avoid
toxicity and the induction of early drug resistance. Chemotherapy
is reserved to treat minimal residual disease postoperatively. Ini-
tial results demonstrated the feasibility and effectiveness of this
approach: a higher objective response rate (> 70%) and consid-
erably less toxicity compared to 131I-MIBG therapy after conven-
tional treatment [40]. 131I-MIBG is equally effective as chemother-
apy in attaining operability of neuroblastoma and the 5 year sur-
vival rate is not worse. Two new multicenter studies integrate up-
front 131I-MIBG therapy in the treatment protocol of neuroblasto-
ma: patients with unresectable stage II and III neuroblastoma re-
ceive 2 cycles of 131I-MIBG only prior to surgery; in patients over 1
year of age, with stage IV and unfavorable prognostic parameters
(high risk group), the 131I-MIBG therapy is intensified and com-
bined with the topoisomerase I inhibitor Topotecan to enhance
the radiation induced cytotoxicity.
Phase I studies of radioimmunotherapy using 131I-UJ13A or
131I-3F8 in small series of patients with stage IV neuroblastoma
resulted in few objective responses and stabilization of disease,
but this was associated with severe side effects and the induction
of HAMA response limited the usefulness of repeated applica-
tion. New developments in radioimmunotherapy of neuroblasto-
ma include the use of chimeric antibodies, such as chCE7 and
ch14.18. In nude mice with SK-N-SH neuroblastoma xenografts
the therapeutic efficacy of 131I-labeled anti-L1-CAM antibody chCE7
compared to 131I-MIBG was demonstrated; the complementarity
of these agents, as shown by comparative scintigraphic studies
in patients, underline the heterogeneity of this disease and may
have implications for radionuclide therapy of neuroblastoma in
the future [24].
Osteosarcoma
Therapeutic bone-seeking radiopharmaceuticals, such as
89Sr-chloride, 186Re-HEDP and 153Sm-EDTMP, may be indicated
for the palliation of painful skeletal metastases of various tumors,
provided that bone scintigraphy shows intense 99mTc-diphospho-
nate uptake at metastatic sites which are painful. In case of meta-
static osteosarcoma, this treatment may be directed at both the
skeletal and extraskeletal metastases (e.g. lung or painful pleural
lesions) [41]. Theoretically, bone seeking agents may also been
used preoperatively in patients with inoperable osteosarcoma, but
in practice chemotherapy is used.
Lymphoma
Although, at this time, radioimmunotherapy of recurrent lym-
phoma is not practiced in children, it should be noted that this
treatment is attaining overall objective response rates of around
70% in adults with recurrent B-cell lymphoma [42]. Several protocols
are undergoing clinical investigation: either immunotherapy using
unlabeled anti-CD20 antibodies, or radioimmunotherapy with non-
myeloablative doses of 131I- or 90Y-labeled anti CD20 or with myeloa-
blative doses of 131I-anti CD20 antibodies,requiring autologous bone
marrow or peripheral stem cell reinfusion. The reported objective re-
sponse rates of radioimmunotherapy are better than those of immu-
Table 3. Pooled results of 131I-MIBG therapy in neural crest tumors (EANM Radionuclide Therapy Committee Workshop, Barcelona, October 1999)
Disease Patients Objective response: Objective response: Subjective response:
Tumor volume  Biochemical  Palliation
Pheochromocytoma 77 51% 68% 68%
Paraganglioma 34 48% 51% 70%
Neuroblastoma 229 51% NA Most patients
Medullary thyroid ca. 29 23% 60% 60%
Carcinoid 159 8% 24% 60%
Other 6 2/6 NA NA
TOTAL 534
NA — not available
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notherapy, and with myeloablative therapy higher than with non-mye-
loablative therapy. It may therefore be a matter of time before such
protocols become active in pediatric oncology too.
Conclusions
The role of nuclear medicine in pediatric oncology is ex-
panding:
— in tumor imaging the focus of interest is shifting from tumor
detection to tumor characterization and early prediction of re-
sponse;
— digital matching of functional parameters (SPECT/PET) with
anatomical parameters (CT/MRI) provides greater accuracy in
detection, staging, follow up and radiation therapy planning;
— as a functional modality nuclear medicine is highly suited for
monitoring the function of organs, which are at risk during
oncological therapy;
— also in children therapeutic nuclear medicine can provide an
effective, systemic, but relatively noninvasive treatment, which
is associated with limited toxicity and few long-term effects;
— pediatric nuclear oncology requires a close collaboration be-
tween pediatricians and nuclear medicine physicians.
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